given that gene expression results indicated some models undergo profound changes with in vivo passage, a general metric of stability was generated so models could be ranked accordingly.
removal of the murine artifacts followed by pairwise analysis of in vitro cells with respective passage  <dig> xenografts and go analysis illustrates the complex interplay that each model has with the host microenvironment.
to illustrate mining strategies supporting therapeutic studies, transcript expression was determined: 1) relative to other models, 2) with successive in vivo passage, and 3) during the in vitro to in vivo transition.
xenograft modelsaffymetrix hg-u <dig> plus  <dig>  arraycdna microarraynci- <dig> cell line screentranscriptomic stabilitytranscriptomic expressionin vitro to in vivo transitionissue-copyright-statementÂ© the author 2014
the utility of monitoring changes in gene expression with extended in vivo tumor passages was illustrated by focused studies of drug resistance mediators and receptor tyrosine kinases.
ranking models according to relative transcript expression in vivo has the potential to improve initial model selection.
forty-nine human tumor xenografts at in vivo passages  <dig>   <dig> and  <dig> were subjected to cdna microarray analysis yielding a dataset of  <dig> affymetrix hg-u <dig> plus  <dig>  arrays.
this study provides strategies to aid selection of xenograft models for therapeutic studies.
these data highlight the dynamic nature of xenograft models and emphasize the importance of maintaining passage consistency throughout experiments.
development of cancer therapeutics partially depends upon selection of appropriate animal models.
therefore, improvements to model selection are beneficial.
lastly, changes occurring during transition from in vitro to in vivo growth may have important consequences for therapeutic studies since targets identified in vitro could be over- or under-represented when tumor cells adapt to in vivo growth.
noteworthy observations included a significant decline in hct- <dig> colon xenograft abcb <dig> transporter expression and increased expression of the kinase kit in a <dig> with serial passage.
for example, combining p <dig> tumor expression data with mutational status could guide selection of tumors for therapeutic studies of agents where p <dig> status purportedly affects efficacy .
